You are using an unsupported browser. Please use the latest version of Chrome, Firefox, Safari or Edge.
Giving Tuesday is almost here!
Support the MGH Fund
Don't wait! Double your impact now - make your gift to the MGH Fund today, and it will be matched dollar-for-dollar.
Giving Tuesday starts in:

Neurology

We provide superior, patient-centered clinical care while rapidly discovering treatments to reduce and eliminate neurological disorders.

The Massachusetts General Hospital Department of Neurology has been at the forefront of many recent advances in its field, including:  

  • Identifying the first genes involved in Alzheimer’s disease and developing techniques to accelerate the identification and evaluation of therapies.
  • Launching the HEALEY ALS Platform Trial, enabling more than one promising amyotrophic lateral sclerosis (ALS) therapy to be tested simultaneously for the first time, significantly reducing the time and cost involved in finding meaningful treatments for ALS.
  • Leading the telestroke movement, providing clinicians everywhere with expert advice to evaluate and treat stroke patients.

Our goal is to be the world’s leading academic neurology department — and a powerful force in diminishing the global toll of morbidity and mortality from neurological disorders.  

Neurology- ALS

Imagine a future where …

  • People with neurological disorders can count on rapid access to the best care and new, effective treatments.
  • We leverage big data, gene editing, brain organoids, novel imaging tools, artificial intelligence and other technologies to improve care for people with neurological disorders and those at risk.
  • Brilliant, diverse and compassionate faculty and staff are encouraged to be bold and make a difference for patients.

With clinicians, scientists and staff who bring unrivaled expertise in neurological research and care, the Department of Neurology is poised to bring this future to life.

Leading the Charge in ALS Therapy Research and Development
Featured Story

Leading the Charge in ALS Therapy Research and Development

Mass General physician-investigators are considered leaders in the research and discovery of novel, effective therapies for patients with amyotrophic lateral sclerosis (ALS). Merit Cudkowicz, MD, MSc, director of the Sean M. Healey & AMG Center for ALS, shares her insights.

Read More

We’re investing in …

neuro exam
Neurology department at work
Jonathan Rosand and Alex Soukas